Whitelogolarge.jpg
UPDATE – The M&A Class Action Firm Continues Investigating the Merger – RFP, SBTX, GBT, EVOP
September 22, 2022 17:26 ET | Monteverde & Associates PC
NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
Whitelogolarge.jpg
The M&A Class Action Firm Continues Investigating the Merger – RFP, SBTX, GBT, EVOP
September 20, 2022 17:27 ET | Monteverde & Associates PC
NEW YORK, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
GBT new logo.png
GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022
September 15, 2022 18:00 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced its support for the Sickle Cell Disease Treatment Centers Act of 2022,...
GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics Conference
September 08, 2022 08:00 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif. and BALTIMORE, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) and the Sickle Cell Disease Association of America, Inc. (SCDAA)...
BES_Mark.jpg
GLOBAL BLOOD THERAPEUTICS, INC. ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of GBT and Encourages Investors to Contact the Firm
August 09, 2022 16:48 ET | Bragar Eagel & Squire
NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
GBT new logo.png
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
August 08, 2022 06:45 ET | Global Blood Therapeutics, Inc.; Pfizer, Inc.
Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion Potential...
GBT new logo.png
GBT Announces New Employment Inducement Grants
August 04, 2022 16:05 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on August 1, 2022, the compensation committee of GBT’s board...
GBT new logo.png
GBT Announces Participation at the Wedbush PacGrow Healthcare Conference
August 03, 2022 16:05 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Wedbush...
GBT new logo.png
GBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022
July 29, 2022 08:00 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 29, 2022 (GLOBE NEWSWIRE) --  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report second quarter 2022 financial results on...
GBT new logo.png
MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
July 26, 2022 03:01 ET | Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA)...